AstraZeneca scientist knighted

31 December 2019
mene_pangalos_astrazeneca_large

Mene Pangalos (pictured above), one of the leaders behind AstraZeneca’s (LSE: AZN) remarkable recent record of successful drug development, has been awarded a knighthood.

Sir Mene’s role is executive vice president of BioPharmaceuticals Research and Development at the Anglo-Swedish drugmaker, a company he joined in 2010.

"He is now accelerating efforts in the digital transformation of R&D"Since then, Sir Mene has been credited for pioneering programs to promote new Open Innovation partnerships with non-governmental and peer organizations, and more than 200 academic institutions, to help drive the UK’s position as a world leader in life sciences R&D.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical